北京市春立正达医疗器械股份有限公司的主营业务是植入性骨科医疗器械的研发、生产与销售。公司的 主要产品是脊柱类、创伤类、关节类、运动医学类、骨修复材料类植入物、手术器械产品、富血小板血 浆（PRP）制备用套装、封闭创伤负压引流套装。2024年获国家工信部认定的人工关节假体制造业单项 冠军企业。 最新一期业绩显示，2025年一季报，公司实现营业收入2.30亿元，同比3.60%；净利润5807.11万元，同 比5.20%，销售毛利率66.69%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13春立医疗55.6856.962.4771.19亿行业平均 52.0649.724.58107.83亿行业中值37.2238.112.4752.18亿1九安医疗10.3010.410.81173.78亿2英科医疗 10.8811.730.97171.88亿3新华医疗14.4413.391.1892.58亿4振德医疗15.4114.530.9855.95亿5奥美医疗 15.5115.201.5956.04亿6山东药玻15.6115.661.79147.65亿7康德莱16.0916.111.3334.68亿8维力医疗 1 ...

Group 1 - The core viewpoint of the article highlights that Chunzhi Medical's stock closed at 18.77 yuan, with a PE ratio of 56.31, marking a new low in 273 days, and a total market capitalization of 7.2 billion yuan [1] - The average PE ratio for the medical device industry is 51.42, with a median of 37.44, placing Chunzhi Medical at the 88th position in the industry ranking [1] - As of the first quarter of 2025, 13 institutions hold shares in Chunzhi Medical, including 8 funds, with a total holding of 31.63 million shares valued at 429 million yuan [1] Group 2 - Chunzhi Medical specializes in the research, production, and sales of implantable orthopedic medical devices, with key products including spinal, trauma, joint, sports medicine implants, and surgical instruments [1] - The latest performance report for the first quarter of 2025 shows that the company achieved revenue of 230 million yuan, a year-on-year increase of 3.60%, and a net profit of 58.07 million yuan, up 5.20%, with a gross profit margin of 66.69% [1] - The company was recognized as a champion enterprise in the artificial joint prosthesis manufacturing industry by the Ministry of Industry and Information Technology in 2024 [1]

北京市春立正达医疗器械股份有限公司的主营业务是植入性骨科医疗器械的研发、生产与销售。公司的 主要产品是脊柱类、创伤类、关节类、运动医学类、骨修复材料类植入物、手术器械产品、富血小板血 浆（PRP）制备用套装、封闭创伤负压引流套装。2024年获国家工信部认定的人工关节假体制造业单项 冠军企业。 最新一期业绩显示，2025年一季报，公司实现营业收入2.30亿元，同比3.60%；净利润5807.11万元，同 比5.20%，销售毛利率66.69%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13春立医疗49.7150.852.2163.56亿行业平均 49.1247.184.49104.96亿行业中值36.0737.112.4149.03亿1英科医疗9.6910.450.86153.16亿2九安医疗 10.1410.250.80171.07亿3新华医疗14.2913.251.1791.61亿4奥美医疗15.1114.811.5554.59亿5康德莱 15.2015.211.2632.76亿6振德医疗15.4114.520.9855.93亿7山东药玻15.5915.641.79147.46亿8维力医疗 16 ...

股东方面，截至2025年3月31日，春立医疗股东户数7167户，较上次增加501户，户均持股市值35.28万 元，户均持股数量2.76万股。 北京市春立正达医疗器械股份有限公司的主营业务是植入性骨科医疗器械的研发、生产与销售。公司的 主要产品是脊柱类、创伤类、关节类、运动医学类、骨修复材料类植入物、手术器械产品、富血小板血 浆（PRP）制备用套装、封闭创伤负压引流套装。2024年获国家工信部认定的人工关节假体制造业单项 冠军企业。 6月18日，春立医疗今日收盘16.49元，下跌2.54%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到49.47倍，总市值63.25亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均49.10倍，行业中值36.43倍，春立医疗排 名第88位。 最新一期业绩显示，2025年一季报，公司实现营业收入2.30亿元，同比3.60%；净利润5807.11万元，同 比5.20%，销售毛利率66.69%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13春立医疗49.4750.612.2063.25亿行业平均 49.1047.114.54105.10亿行业中 ...

Group 1 - The core viewpoint of the article highlights that Chunli Medical's stock closed at 15.62 yuan, with a 2.83% increase, and a rolling PE ratio of 46.86 times, with a total market value of 5.991 billion yuan [1] - The average PE ratio for the medical device industry is 50.06 times, with a median of 36.80 times, placing Chunli Medical at the 87th position in the industry ranking [1] - As of the first quarter of 2025, 13 institutions hold shares in Chunli Medical, including 8 funds, 4 others, and 1 brokerage, with a total holding of 31.6307 million shares valued at 429 million yuan [1] Group 2 - Chunli Medical specializes in the research, production, and sales of implantable orthopedic medical devices, with main products including spinal, trauma, joint, sports medicine implants, bone repair materials, surgical instruments, PRP preparation kits, and negative pressure drainage kits [1] - The company was recognized as a champion enterprise in the artificial joint prosthesis manufacturing industry by the Ministry of Industry and Information Technology in 2024 [1] - The latest performance report for the first quarter of 2025 shows that the company achieved an operating income of 230 million yuan, a year-on-year increase of 3.60%, and a net profit of 58.0711 million yuan, a year-on-year increase of 5.20%, with a gross sales margin of 66.69% [1]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Spring Medical, indicating a decline in stock price and a relatively high PE ratio compared to industry averages [1][2] - As of May 8, Spring Medical's stock closed at 15.48 yuan, down 2.03%, with a rolling PE ratio of 46.44 times and a total market capitalization of 5.938 billion yuan [1] - The average PE ratio for the medical device industry is 49.20 times, with a median of 36.56 times, placing Spring Medical at the 87th position in the industry ranking [1][2] Group 2 - As of March 31, 2025, Spring Medical had 7,167 shareholders, an increase of 501 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] - The company specializes in the research, production, and sales of implantable orthopedic medical devices, including spinal, trauma, joint, sports medicine, bone repair materials, surgical instruments, and PRP preparation kits [1] - In the latest quarterly report for Q1 2025, Spring Medical achieved an operating revenue of 230 million yuan, a year-on-year increase of 3.60%, and a net profit of 58.0711 million yuan, reflecting a year-on-year growth of 5.20%, with a gross profit margin of 66.69% [1]

Group 1 - The core viewpoint of the articles highlights that Chunli Medical's stock price has increased by 4.03% to 15.76 yuan, with a rolling PE ratio of 47.28, marking a new low in 140 days, and a total market capitalization of 6.045 billion yuan [1][2] - Chunli Medical ranks 87th in the medical device industry based on PE ratio, with the industry average at 48.90 and the median at 36.41 [1][2] - As of the first quarter of 2025, 13 institutions hold shares in Chunli Medical, including 8 funds, with a total holding of 31.6307 million shares valued at 429 million yuan [1] Group 2 - Chunli Medical specializes in the research, production, and sales of implantable orthopedic medical devices, with key products including spinal, trauma, joint, sports medicine implants, and surgical instruments [1] - The company achieved a revenue of 230 million yuan in the first quarter of 2025, reflecting a year-on-year growth of 3.60%, and a net profit of 58.0711 million yuan, with a year-on-year increase of 5.20% and a gross margin of 66.69% [1]

近期，一种名为"高潮针"的医美产品冲上热搜。 据"红星新闻"报道，网传消息称，多地女性开打高潮针，相关预约爆满。有商家介绍，高潮针是在阴道 内的敏感点位注射胶原蛋白，以帮助提升性快感和高潮，价格从数千元至万元不等。 暨南大学附属第一医院生殖内分泌科主任高绿芬告诉"医学界"，医学上没有"高潮针"这个概念。让她担 忧的是，有些女性被没有指征的用药，一些没有资质的非医疗机构为了盈利，使用不正确或不合格的填 充物进行注射。 "（这是）存在好几年的危险且诱人的项目。早先是偷偷摸摸搞，近几个月开始大张旗鼓地搞。"前北京 三甲医院妇产科医生、科普大V"六层楼"发文指出，相关项目"技术不成熟、原理不扎实、效果不明 确、风险一大堆。" "这不是一个新鲜事物" 4月28日，"医学界"在某社交平台搜索发现，以"高潮针"为关键词的笔记基本被清空，但仍有不少自称 消费者的人在分享注射体验，疑似引流至相关医美机构。 其中一部分"高潮针"的主要成分是高浓度血小板血浆（Platelet-rich plasma，PRP），又称富血小板血 浆，是在提取全血并经离心机分离各成分后，提取的富含血小板的血浆蛋白浓缩液。 这并不是一个新鲜事物，厦门海峡 ...

Group 1 - The core viewpoint of the article highlights that Chunzhi Medical's stock closed at 14.28 yuan, down 3.32%, with a rolling PE ratio of 43.82 times and a total market value of 5.477 billion yuan [1] - The average PE ratio for the medical device industry is 46.40 times, with a median of 34.81 times, placing Chunzhi Medical at the 85th position in the industry ranking [1] - As of the 2024 annual report, four institutions hold shares in Chunzhi Medical, with a total of 382,700 shares valued at 0.05 million yuan [1] Group 2 - Chunzhi Medical specializes in the research, production, and sales of implantable orthopedic medical devices, including spinal, trauma, joint, sports medicine, bone repair materials, surgical instruments, and PRP preparation kits [1] - The latest performance report for 2024 shows that the company achieved operating revenue of 806 million yuan, a year-on-year decrease of 33.32%, and a net profit of 125 million yuan, down 55.01%, with a gross profit margin of 66.63% [1]